'This has to change': New dad, grieving mom fighting for Alberta to cover rare cancer treatment
A new dad from the Calgary area is pressing the province to fund a new cancer treatment that might improve his chances of seeing his daughter grow up.
Chris Dyment was diagnosed with bile duct cancer in April 2023 and after 12 rounds of chemotherapy, his treatment will soon end.
The 34-year-old’s daughter Courtney was born earlier this month.
“I look at my daughter and I want to be there with her," he said.
“Bile duct cancer is a very aggressive cancer and the percentages aren’t very high to begin with, so any percentage is better than none.”
Bile duct cancer, or cholangiocarcinoma (CCA), is a rare, aggressive cancer currently treated in Alberta by one drug, but if it’s unsuccessful, there is no second treatment option.
Health Canada has approved the use of the targeted therapy Pemigatinib (Pemazyre), but Alberta does not currently cover the roughly $15,000 per month cost.
Dyment desperately wants to be there for his daughter, but he knows his survival rate will drop dramatically without another treatment option.
"Obviously, I want to see her grow and without this drug, it’s almost impossible," he said.
Chris Dyment with his daughter Courtney, who was born on March 1. (Courtesy: Chris Dyment)
The pilot has not been able to work since his diagnosis and will likely be unable to afford Pemigatinib (Pemazyre).
“If this drug works, it really works. People have gotten into surgery which has saved their lives and then I can be there with my daughter when she gets married," he said.
Fighting for change
Brenda Clayton’s oldest daughter, Rebecca, was diagnosed with the rare cancer in 2020 and died in 2021, six and half months after her first-line treatment ended.
Her family has since started the charity Cholangio-hepatocellular Carcinoma Canada.
“I don’t want to see other people go through what Rebecca went through,” Clayton said.
Rebecca (front left) and Brenda (front right) Clayton seen in a family photo. Rebecca died from bile duct cancer in 2021. (Courtesy: Brenda Clayton)
Clayton said patients have an average of five months of survival off treatment unless they can find a treatment elsewhere in the world.
“This cancer is one of the few that does not have a second-line therapy to use,” she said. “This has to change and our Canadians deserve a chance at life.”
She said Quebec and countries including the United States, United Kingdom and China cover the cost of Pemigatinib.
Clayton said she will meet with Alberta Health Minister Adriana Lagrange on April 2 to discuss this.
“We recognize that people living with bile duct cancer have few treatment options and are seeking new and better ways to address this disease. At this time, Alberta is aligned with the pan-Canadian Oncology Drug Review’s Expert Review Committee,” Alberta Health said in a statement to CTV News.
“However, the pan-Canadian Pharmaceutical Alliance is presently negotiating a pricing agreement with the drug’s manufacturer. If a pricing agreement is reached, each province and territory, including Alberta, will take into consideration both the committee’s recommendation and the pricing agreement when deciding whether or not to list the drug.”
In 2022, the pan-Canadian Oncology Drug Review’s Expert Review Committee recommended Pemazyre (pemigatinib) not be reimbursed on government-sponsored drug plans due to some uncertainty about the drug’s benefits.
On March 7, 2024, the pan-Canadian Pharmaceutical Alliance started price negotiations with the manufacturer of Pemazyre.
Clayton said aside from Dyment she knows of one other Albertan waiting for the treatment.
She has also reached out to the health ministers in every province and territory in Canada, hoping to be part of a more promising future for people facing this disease.
“When she died she asked us to please continue the fight against cholangiocarcinoma.”
Dyment said he also contacted the health minister and received a similar statement as the one provided to CTV News.
CTVNews.ca Top Stories
NEW Is there a cost to convenience? Canada approves new cancer immunotherapy treatment
A new cancer treatment recently approved in Canada promises to cut treatment time down to just minutes, but experts have differing opinions on whether it's what's best for patients.
Air Canada walks back new seat selection policy change after backlash
Air Canada has paused a new seat selection fee for travellers booked on the lowest fares just days after implementing it.
DEVELOPING Canada's GDP rises amid expert fears of rate-hike recession
Canada's GDP rose 0.2 per cent in February, driven by a rebound in transportation and warehousing, which saw the largest recorded month-to-month rise in over a year at 1.4 per cent.
Canada's new dental program offering hope of free care to millions but many dentists aren't signed up
A new Canadian dental care program is offering the hope of free care to millions, but while 1.7 million people have signed up for the plan, only about 5,000 dentists have done the same.
Province boots mayor and council in small northern Ont. town out of office
An ongoing municipal strike, court battles and revolt by half of council has prompted the province to oust the mayor and council in Black River-Matheson.
'Fatalities' reported following wrong-way collision on Highway 401, SIU called in: police
Ontario's Special Investigations Unit has been called in following a deadly wrong-way collision on Highway 401 in Whitby on Monday night, say police.
Winner of US$1.3 billion Powerball jackpot is an immigrant from Laos who has cancer
One of the winners of a historic US$1.3 billion Powerball jackpot last month is an immigrant from Laos who has had cancer for eight years and had his latest chemotherapy treatment last week.
King Charles III returns to public duties with a trip to a cancer charity
King Charles III returned to public duties on Tuesday, visiting a cancer treatment charity and beginning his carefully managed comeback after the monarch's own cancer diagnosis sidelined him for three months.
NDP says Ottawa's new grocery task force isn't living up to government promises
The federal government says the task force it created to monitor and investigate grocery retailers' practices has not conducted any probes and doesn't have a mandate to take enforcement action.